Reference : Place du traitement substitutif de la menopause 1 an apres la publication des resulta...
Scientific journals : Article
Human health sciences : Reproductive medicine (gynecology, andrology, obstetrics)
http://hdl.handle.net/2268/21465
Place du traitement substitutif de la menopause 1 an apres la publication des resultats de l'etude WHI (Women's Health Initiative)
French
[en] Hormone Replacement Therapy One Year after the Results of the Women's Health Initiative
Pintiaux, Axelle [Centre Hospitalier Universitaire de Liège - CHU > > Gynécologie-Obstétrique CHR >]
Van den Brule, F. [> > > >]
Foidart, Jean-Michel mailto [Université de Liège - ULg > Département des sciences cliniques > Gynécologie - Obstétrique >]
Gaspard, Ulysse mailto [Université de Liège - ULg > Services généraux (Faculté de médecine) > Relations académiques et scientifiques (Médecine)]
Sep-2003
Revue Médicale de Liège
Hopital de Baviere
58
9
572-5
Yes (verified by ORBi)
0370-629X
Liège
Belgique
[en] Hormone replacement therapy ; conjugated estrogens and medroprogesterone acetate ; Coronary heart disease ; cerebro-vascular disease ; venous thromboembolism ; Breast cancer ; Colorectal cancer ; Osteoporosis ; Dementia
[en] The currently reported data concerning the large WHI randomized controlled trial compare the impact of continuous combined conjugated estrogens + medroxyprogesterone acetate vs placebo in postmenopausal women. These results appear largely pessimistic. After 5.2 years of hormone replacement, an excess of coronary heart disease, cerebrovascular disease, venous thromboembolism, breast cancer incidence and extension, mild cognitive impairment and dementia is recorded. By contrast, osteoporotic fracture risk and colorectal cancer are decreased during hormone replacement. Accordingly, this hormonal treatment can no longer be recommended on a long term basis, except after extensive risk-benefit balance evaluation. It should no longer be prescribed for prevention of chronic diseases. It remains indicated during 4-5 years for relief of vasomotor symptoms, genital atrophy and, potentially, for some aspects of quality of life. HRT should probably be prescribed in minimal-effective dosages; new regimens, routes of administration, new compounds and associations should be envisaged in order to avoid cardiovascular or breast problems. However these new approaches ask for thorough validation studies.
http://hdl.handle.net/2268/21465

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Pintiaux A 2003.pdfPublisher postprint432.45 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.